Treatment of Uncomplicated Gonorrhea
For uncomplicated gonorrhea, treat with ceftriaxone 500 mg intramuscularly as a single dose, plus doxycycline 100 mg orally twice daily for 7 days if chlamydial coinfection has not been excluded. 1, 2
Current First-Line Regimen
The treatment landscape for gonorrhea has evolved significantly due to antimicrobial resistance concerns. The most recent U.S. guidelines (2020-2021) represent a critical shift from previous dual-therapy recommendations:
- Ceftriaxone 500 mg IM once is now the primary treatment for all anatomic sites (urogenital, rectal, and pharyngeal) 1, 2
- Add doxycycline 100 mg orally twice daily for 7 days if Chlamydia trachomatis coinfection has not been ruled out 1, 2
This represents an increase from the previous 250 mg ceftriaxone dose and abandonment of routine azithromycin co-treatment due to rapidly rising azithromycin resistance (nearly 5% of isolates with elevated MICs by 2018) 1. The higher ceftriaxone dose provides greater antimicrobial stewardship while maintaining efficacy, as U.S. surveillance data show <0.1% of isolates with concerning ceftriaxone MICs 1.
Why This Regimen Works
Ceftriaxone maintains excellent activity: U.S. surveillance through the Gonococcal Isolate Surveillance Project shows stable ceftriaxone MICs with minimal resistance, unlike the concerning azithromycin resistance trends 1. The 500 mg dose provides robust bactericidal levels with a therapeutic reserve against potential resistance emergence.
Doxycycline addresses chlamydia, not gonorrhea: This is crucial to understand—doxycycline is added for presumptive chlamydial treatment (which frequently coexists), not as dual therapy for gonorrhea itself 1, 2. If chlamydia has been definitively excluded by testing, doxycycline can be omitted.
Alternative Regimens (Limited Options)
For patients with cephalosporin allergies, options are severely constrained:
- Gentamicin 240 mg IM plus azithromycin 2 g orally can be considered for urogenital and rectal infections if the isolate is azithromycin-susceptible 3
- No recommended alternatives exist for pharyngeal gonorrhea in cephalosporin-allergic patients 1
Critical caveat: Azithromycin resistance varies dramatically by region (4-7% in North America, up to 66% in parts of East Asia), making it unreliable as monotherapy or in dual regimens in many settings 3.
Anatomic Site Considerations
Pharyngeal infections are the Achilles' heel: Pharyngeal gonorrhea is harder to eradicate than urogenital or rectal infections 4, 5. The 500 mg ceftriaxone dose addresses this, as lower doses and oral cephalosporins have historically shown reduced pharyngeal efficacy. Always test the pharynx in treatment failures, as pharyngeal infections are usually asymptomatic and facilitate transmission of resistant strains 3.
What NOT to Use
- Fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin): Once first-line agents 4, 6, 5, these are no longer recommended due to widespread resistance
- Azithromycin monotherapy: Insufficient efficacy (only 93% cure rate at 1 g dose) and rising resistance 5
- Cefixime 400 mg oral: While previously recommended 4, 6, 5, this provides lower and less sustained bactericidal levels than injectable ceftriaxone and is not part of current U.S. guidelines
- Spectinomycin: Expensive, injectable, and only 52% effective against pharyngeal infections 5
Emerging Therapies
Two novel oral agents show promise in phase 3 trials:
- Zoliflodacin 3 g oral (single dose): Demonstrated non-inferiority to ceftriaxone 500 mg plus azithromycin 1 g for urogenital gonorrhea with 90.9% cure rates 7, 8
- Gepotidacin (two 3 g oral doses 10-12 hours apart): Showed 92.6% microbiological success, non-inferior to ceftriaxone plus azithromycin 9
Both offer oral alternatives with novel mechanisms of action, though neither is yet FDA-approved for routine use.
Essential Follow-Up
- Test of cure is NOT routinely needed if patients received recommended treatment and are asymptomatic 5
- Persistent symptoms warrant culture with susceptibility testing and reporting to local health departments 4, 1
- Retest in 3-6 months due to high reinfection rates (most "treatment failures" are actually reinfections) 5, 10
- Test for other STIs including HIV, syphilis, and chlamydia at initial diagnosis 5, 10
Partner Management
All sexual partners within 60 days of symptom onset or diagnosis must be evaluated and treated, even if asymptomatic 5. Patients should abstain from sexual activity until both they and their partners complete treatment and are symptom-free 5.